PT  - JOURNAL ARTICLE
AU  - Schell, Carl Otto
AU  - Khalid, Karima
AU  - Wharton-Smith, Alexandra
AU  - Oliwa, Jacquie Narotso
AU  - Sawe, Hendry Robert
AU  - Roy, Nobhojit
AU  - Sanga, Alex
AU  - Marshall, John C.
AU  - Rylance, Jamie
AU  - Hanson, Claudia
AU  - Kayambankadzanja, Raphael Kazidule
AU  - Jirwe, Maria
AU  - Baker, Tim
AU - the EECC Collaborators
TI  - Essential Emergency and Critical Care – a consensus among global clinical experts
AID  - 10.1101/2021.03.18.21253191
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.18.21253191
4099  - http://medrxiv.org/content/early/2021/03/25/2021.03.18.21253191.short
4100  - http://medrxiv.org/content/early/2021/03/25/2021.03.18.21253191.full
AB  - Background Globally, critical illness results in millions of deaths every year. Although many of these deaths are potentially preventable, the basic, life-saving care of critically ill patients can be overlooked in health systems. Essential and Emergency Care (EECC) has been devised as the care that should be provided to all critically ill patients in all hospitals in the world. EECC includes the effective care of low-cost and low-complexity for the identification and timely treatment of critically ill patients across all medical specialities. This study aimed to specify the content of EECC and additionally, given the surge of critical illness in the ongoing pandemic, the essential diagnosis-specific care for critically ill patients with COVID-19.Methods A Delphi process was conducted to seek consensus (>90% agreement) among a diverse panel of global clinical experts. The panel was asked to iteratively rate proposed treatments and actions based on previous guidelines and the WHO’s Basic Emergency Care. The output from the Delphi was adapted iteratively with specialist reviewers into a coherent, user-friendly, and feasible EECC package of clinical processes plus a list of hospital resource requirements.Results The 272 experts in the Delphi panel had clinical experience in different acute medical specialties from 59 countries and from all resource settings. The agreed EECC package contains 40 clinical processes and 67 hospital readiness requirements. The essential diagnosis-specific care of critically ill COVID-19 patients has an additional 7 clinical processes and 9 hospital readiness requirements.Conclusion The study has specified the content of the essential emergency and critical care that should be provided to all critically ill patients. Implementation of EECC could be an effective strategy to reduce preventable deaths worldwide. As critically ill patients have high mortality rates in all hospital settings, especially where trained staff or resources are limited, even small improvements would have a large impact on survival. EECC has a vital role in the effective scale-up of oxygen and other care for critically ill patients in the COVID-19 pandemic. Policy makers should prioritise EECC, increase its coverage in hospitals, and include EECC as a component of universal health coverage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Wellcome Trust [221571/Z/20/Z] COS received grants from Centre for Clinical Reserach Sormland, Uppsala UniversityAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:London School of Hygiene and Tropical Medicine Research Ethics Committee (Ref: 22575)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available in supplementary tables